ArticleFrontiers in endocrinology2024
A comparison of the performance of
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.Journal of the American Heart Association · 2026Pooled it
- AVS-referenced diagnostic performance ofFrontiers in endocrinology · 2026Pooled it
- Article
- Nuclear Medicine Tracers Targeting Tumor-Associated Macrophages.Pharmaceutics · 2026Review
- Clinical value of multi-time-pointEndocrine · 2026Article
- ⁶⁸GA-Pentixafor PET/CT: a non-invasive molecular alternative to adrenal venous sampling in primary aldosteronism.EJNMMI reports · 2026Review
- A Novel Non-Invasive Diagnostic Tool for Determining the Subtype of Primary Aldosteronism UsingWorld journal of nuclear medicine · 2026Article
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
- 68 Ga-pentixafor PET/CT versus adrenal venous sampling in guiding surgical management for primary aldosteronism: a prospective cohort study on postoperative outcomes.International journal of surgery (London, England) · 2026Article
- Real world experience with [Frontiers in endocrinology · 2026Article
- Identifying unilateral aldosterone-producing adenomas using published algorithms and imaging: a systematic review and meta-analysis.Endocrine connections · 2025Article
- Is CXCR4-targetedEJNMMI research · 2025Article
- Establishment and evaluation of a patient-derived organoids-based xenograft model of primary aldosteronism using [Journal of translational medicine · 2025Article
- CXCR4-directed PET withEndocrine · 2025Article
- The prognostic value of CXCR4 PET/CT imaging in unilateral primary aldosteronism patients after adrenalectomy.EJNMMI research · 2025Article
- Article
- Recent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors.Mini reviews in medicinal chemistry · 2025Review
- Case Report: Anomalous drainage vein sampling for diagnosing aldosterone-producing lesions undetectable by segmental adrenal venous sampling in a two-case series.Frontiers in radiology · 2025Article
- Clinical diagnosis and treatment of a patient with hypertension, hypokalemia, and bilateral adrenal adenomas.Frontiers in endocrinology · 2025Article
- Gallium-68-Pentixafor PET/CT for Subtyping Diagnosis of Primary Aldosteronism: A Pictorial Essay.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the diagnostic efficiency and prognostic value of Methods: We prospectively recruited 26 patients diagnosed with PA. All patients underwent Results: On total, 19 patients were diagnosed with UPA; of these, 13 patients were lateralized by both PET/CT and AVS, four patients were lateralized by PET-only, and two by AVS-only. Seven subjects with no lateralization on AVS and PET received medical therapy. All patients achieved complete biochemical success except one with nodular hyperplasia lateralized by AVS alone. The consistency between PET/CT and AVS outcomes was 77% (20/26). Moreover, CYP11B2-positive nodules were all CXCR4-positive and showed positive findings on PET. Patients who achieved complete biochemical and clinical success had a higher uptake on PET as well as stronger expression levels of CXCR4 and CYP11B2. Conclusion: Our analysis showed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.